We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical observation of docetaxel or gemcitabine combined with cisplatin in the chemotherapy after surgery for stage II-III non-small cell lung cancer.
- Authors
Qiuqiang Chen; Xuexian Ji; Xiao Zhou; Qilin Shi; Huanming Yu; Hengqin Fu
- Abstract
Objective: This study aimed to compare the efficacy and toxicity of docetaxel combined with cisplatin (DP) and gemcitabine combined with cisplatin (GP) in postoperative chemotherapy after surgery of nonsmall cell lung cancer (NSCLC). Methods: A total of 92 patients diagnosed with NSCLC after surgery were enrolled, and they were treated with DP (DP group) and GP (GP group). The efficacy and toxicity of the medications were then compared. Results: Approximately 92.4% (85 out of 92) of the patients received chemotherapy for more than three weeks. In DP and GP groups, the incidence rates of grade III-IV thrombocytopenia were 24.4% and 6.38%, respectively, whereas the incidence rates of alopecia were 88.9% and 25.5%, respectively. The difference between the two groups was statistically significant (P < 0.05). Disease-free survival rates in DP group in one and two years were 76.5% and 50.47%, respectively, whereas in GP group were 77.8% and 49.52%, respectively. No significant difference was observed between the two groups (P > 0.05). Conclusion: These results showed similar disease-free survival rates of DP and GP therapies in one and two years after surgery for NSCLC. However, DP group exhibited higher incidence of grade III-IV thrombocytopenia and alopecia than GP group. Therefore, we should select a specific treatment for each patient according to individual differences.
- Subjects
DOCETAXEL; CISPLATIN; CANCER chemotherapy; NON-small-cell lung carcinoma; DRUG efficacy; POSTOPERATIVE care; SURVIVAL analysis (Biometry)
- Publication
Pakistan Journal of Medical Sciences, 2015, Vol 31, Issue 5, p1
- ISSN
1682-024X
- Publication type
Article
- DOI
10.12669/pjms.315.7380